Risks faced by women using anabolic steroids in Australia
A new study published in Drug and Alcohol Review has revealed critical insights into the challenges and risks faced by women who use anabolic-androgenic steroids (AAS).Readmore
This site is part of the Siconnects Division of Sciinov Group
This site is operated by a business or businesses owned by Sciinov Group and all copyright resides with them.
ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR
28 Aug
2024
Risks faced by women using anabolic steroids in Australia
A new study published in Drug and Alcohol Review has revealed critical insights into the challenges and risks faced by women who use anabolic-androgenic steroids (AAS).Readmore
10 Sep
2024
Patients receiving steroids are more than twice as likely to develop diabetes, UK study has found
Patients who are being treated with systemic glucocorticoids are more than twice as likely to develop diabetes as those not receiving the treatment, a new study by researchers at the Radcliffe Department of Medicine’s Diabetes Trial Unit has found.Readmore
13 Feb
2024
Anabolic steroid use can increase heart disease risk
Taking testosterone may increase the risk of atrial fibrillation in individuals with an existing predispositionReadmore
3 Jun
2024
About 65% of men who stop anabolic steroids restart, likely due to withdrawal symptoms. Worsened mental health and sexual function should be targeted during the first year of steroid cessation.Readmore
21 Aug
2024
Sports Controversy:Jannik Sinner Avoids Suspension After Steroid Tests
World No. 1 faces backlash and penalties following two positive doping tests without intentional violationReadmore
25 Apr
2024
Neurodevelopmental Outcomes After late preterm antenatal corticosteroids: The ALPS follow-up studyReadmore
13 Feb
2024
Anabolic steroid use can increase heart disease risk: A Researchers led by University of Birmingham
Taking testosterone may increase the risk of atrial fibrillation in individuals with an existing predispositionReadmore
05 Jan
2024
Key takeaways: - 96% of patients maintained reductions through 48 weeks. - 91% of patients had no exacerbations while tapering their doses. - The intervention and reference groups had similar rates of adverse events.Readmore